I am trying to find data indicating whether premenopausal HR+ HER2+ breast cancer patients had better outcomes on tamoxifen versus ovarian suppression or ablation or removal, + or - aromatase inhibitors (if data available). All trials I have seen so far did not distinguish that subgroup. Because recent research from at least 3 different researchers is showing clear stimulation of at least 2 different HER2+ cell lines, BT474 and SKBR3 by normal concentrations of tamoxifen I am concerned.
If anyone can find information about this I would appreciate it.
Since the targeted therapies for HER2+ breast cancer do not readily cross the blood-brain-barrier, but tamoxifen does, the possibility that tamoxifen may be stimulating those brain or lepto-meningeal metastases seems a prudent and urgent question to ask.
Thank you!
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology